Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses.

Pan PY, Chen HM, Chen SH.

Oncoimmunology. 2013 Aug 1;2(8):e25083. Epub 2013 May 28.

2.

Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy.

Eisenstein S, Coakley BA, Briley-Saebo K, Ma G, Chen HM, Meseck M, Ward S, Divino C, Woo S, Chen SH, Pan PY.

Cancer Res. 2013 Aug 15;73(16):5003-15. doi: 10.1158/0008-5472.CAN-12-1597. Epub 2013 Mar 27.

3.

Myeloid-derived suppressor cells: Cellular missiles to target tumors.

Chandra D, Gravekamp C.

Oncoimmunology. 2013 Nov 1;2(11):e26967. Epub 2013 Nov 6. Review.

4.

Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles.

Loskog A.

Viruses. 2015 Nov 6;7(11):5780-91. doi: 10.3390/v7112899. Review.

5.

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.

Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Gene Ther. 2008 Apr;15(8):604-16. doi: 10.1038/sj.gt.3303098. Epub 2008 Feb 28.

6.

Myeloid derived suppressor cells in chronic myeloid leukemia.

Giallongo C, Parrinello N, Brundo MV, Raccuia SA, Di Rosa M, La Cava P, Tibullo D.

Front Oncol. 2015 May 15;5:107. doi: 10.3389/fonc.2015.00107. eCollection 2015. Review.

7.

Myeloid-derived suppressor cells: the dark knight or the joker in viral infections?

Goh C, Narayanan S, Hahn YS.

Immunol Rev. 2013 Sep;255(1):210-21. doi: 10.1111/imr.12084. Review.

8.
9.

Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells.

Xiao P, Wan X, Cui B, Liu Y, Qiu C, Rong J, Zheng M, Song Y, Chen L, He J, Tan Q, Wang X, Shao X, Liu Y, Cao X, Wang Q.

Oncoimmunology. 2015 Jun 24;5(1):e1063772. eCollection 2016.

10.

Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells.

Kullberg M, Martinson H, Mann K, Anchordoquy TJ.

Nanomedicine. 2015 Aug;11(6):1355-63. doi: 10.1016/j.nano.2015.03.010. Epub 2015 Apr 1.

11.

Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systems.

Wei MQ, Ren R, Good D, Anné J.

Genet Vaccines Ther. 2008 Feb 17;6:8. doi: 10.1186/1479-0556-6-8.

12.

Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.

Yu N, Puckett S, Antinozzi PA, Cramer SD, Lyles DS.

J Virol. 2015 May;89(10):5250-63. doi: 10.1128/JVI.00257-15. Epub 2015 Mar 4.

13.

Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice.

Hamilton MJ, Banáth JP, Lam V, Lepard NE, Krystal G, Bennewith KL.

Cancer Immunol Immunother. 2012 May;61(5):643-54. doi: 10.1007/s00262-011-1125-0. Epub 2011 Oct 22.

PMID:
22021068
14.

Immune cells: more than simple carriers for systemic delivery of oncolytic viruses.

Eisenstein S, Chen SH, Pan PY.

Oncolytic Virother. 2014;3:83-91.

15.

TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, Jones J, D'Apuzzo M, Forman S, Kortylewski M.

Clin Cancer Res. 2015 Aug 15;21(16):3771-82. doi: 10.1158/1078-0432.CCR-14-3145. Epub 2015 May 12.

16.

PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses.

Sobol PT, Hummel JL, Rodrigues RM, Mossman KL.

Gene Ther. 2009 Sep;16(9):1077-87. doi: 10.1038/gt.2009.68. Epub 2009 May 28.

PMID:
19474810
17.

Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin.

Zhou J, Donatelli SS, Gilvary DL, Tejera MM, Eksioglu EA, Chen X, Coppola D, Wei S, Djeu JY.

Sci Rep. 2016 Jul 13;6:29521. doi: 10.1038/srep29521.

18.

Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.

Power AT, Bell JC.

Gene Ther. 2008 May;15(10):772-9. doi: 10.1038/gt.2008.40. Epub 2008 Mar 27. Review.

PMID:
18369325
19.

Role of myeloid-derived suppressor cells in tumor immunotherapy.

Martin F, Apetoh L, Ghiringhelli F.

Immunotherapy. 2012 Jan;4(1):43-57. doi: 10.2217/imt.11.154. Review.

PMID:
22150000
20.

Aminoacyl-tRNA synthetase-interacting multifunctional protein 1 suppresses tumor growth in breast cancer-bearing mice by negatively regulating myeloid-derived suppressor cell functions.

Hong HJ, Lim HX, Song JH, Lee A, Kim E, Cho D, Cohen EP, Kim TS.

Cancer Immunol Immunother. 2016 Jan;65(1):61-72. doi: 10.1007/s00262-015-1777-2. Epub 2015 Nov 27.

PMID:
26613952

Supplemental Content

Support Center